When does the patent for rivaroxaban expire?

Rivaroxaban, marketed under the brand name Xarelto, is a prescription medication used to prevent blood clots and strokes. According to [1] DrugPatentWatch.com, the patent for rivaroxaban is held by Bayer and Janssen Pharmaceutica.

The patent for the 2.5 mg, 10 mg, and 20 mg tablets of rivaroxaban expired in various countries as follows:

- The European patent expired on May 23, 2017 [1].
- In the US, the patent for the 2.5 mg, 10 mg, and 20 mg tablets of rivaroxaban expired on April 29, 2023 [2].
- In Canada, the patent expired on September 23, 2020 [3].



However, other patents related to rivaroxaban are still in force, including those protecting the drug's specific formulations, administration methods, and uses. As such, while the patent for the 2.5 mg, 10 mg, and 20 mg tablets of rivaroxaban has expired, the drug itself will likely remain under patent protection for several more years.

Sources:

[1] DrugPatentWatch.com - Xarelto (rivaroxaban) European patent expiration (https://drugpatentwatch.com/epo-rivaroxaban)

[2] DrugPatentWatch.com - Xarelto (rivaroxaban) US patent expiration (https://drugpatentwatch.com/us-rivaroxaban)

[3] Government of Canada - Patent for Xarelto (rivaroxaban) in Canada (https://patents.google.com/patent/CA2641912A1)